{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:49:11Z","timestamp":1781106551821,"version":"3.54.1"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, the treatment of migraine has experienced a breakthrough in the development of drugs that target the calcitonin gene\u2010related peptide (CGRP) signaling pathway. Monoclonal antibodies against the receptor or ligand have been developed for the preventive treatment of migraine; whereas, orally administered small molecule CGRP receptor antagonists, called gepants, have been developed for both acute and\/or preventive treatment. Both modalities have demonstrated safe and effective treatment of migraine, reducing the number of migraine days for patients as well as reducing symptoms and improving patient function and overall quality of life. Here, we provide an abridged review of ubrogepant, an oral CGRP receptor antagonist, approved for the acute treatment of migraine. We briefly summarize the role of CGRP in migraine pathophysiology, describing the mechanism of action of ubrogepant in the context of this pathway, the clinical pharmacology properties and the clinical development and outcomes, including safety, efficacy, pharmacokinetics, and pharmacodynamics, that supported ubrogepant's approval.<\/jats:p>","DOI":"10.1111\/cts.13675","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T11:20:11Z","timestamp":1704885611000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ubrogepant: Mechanism of action, clinical and translational science"],"prefix":"10.1111","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8267-9210","authenticated-orcid":false,"given":"Ramesh","family":"Boinpally","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0147-8933","authenticated-orcid":false,"given":"Mohamad","family":"Shebley","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-8878","authenticated-orcid":false,"given":"Joel","family":"Trugman","sequence":"additional","affiliation":[{"name":"Clinical Development AbbVie  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2015"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30185-1"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92692-8"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/298240a0"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-018-0676-y"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410280213"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/117.3.427"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779544"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703110"},{"key":"e_1_2_14_12_1","volume-title":"Calcitonin Gene\u2010Related Peptide (CGRP) Mechanisms","year":"2019"},{"key":"e_1_2_14_13_1","first-page":"160","article-title":"Characterization of Ubrogepant: a potent and selective antagonist of the human calcitonin GeneRelated peptide receptor","volume":"373","author":"Moore E","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_14_14_1","first-page":"S8","article-title":"Pharmacology and pharmacokinetics of Ubrogepant: a potent, selective calcitonin gene\u2010related peptide receptor antagonist for the acute treatment of migraine","volume":"69","author":"Blumenfeld AM","year":"2020","journal-title":"J Fam Pract"},{"key":"e_1_2_14_15_1","volume-title":"UBRELVY Product Monograph","year":"2022"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813049"},{"key":"e_1_2_14_17_1","unstructured":"Allergan USA Inc.UBRELVY (ubrogepant) [package insert]. U.S. Food and Drug Administration. Revised December 2019. Accessed May 30 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211765s000lbl.pdf"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14433"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02939.x"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(97)00108-5"},{"key":"e_1_2_14_21_1","article-title":"Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: results from phase 1 studies","volume":"6","author":"Boinpally R","year":"2023","journal-title":"Cephalalgia Rep"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420970523"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12730"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.16711"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01923-3"},{"key":"e_1_2_14_26_1","doi-asserted-by":"crossref","unstructured":"DodickDW GoadsbyPJ SchwedtTJ et\u00a0al.Ubrogepant for the acute treatment of migraine when administered during the prodrome (premonitory phase): results from a phase 3 randomized double\u2010blind placebo\u2010controlled crossover study. Abstract presented at: 2023 AAN Annual Meeting; April 22\u201027 2023; Boston MA Abstract S47.001.","DOI":"10.1212\/WNL.0000000000202043"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14062"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn307"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420970889"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102416653233"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T18:42:45Z","timestamp":1706121765000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/cts.13675"],"URL":"https:\/\/doi.org\/10.1111\/cts.13675","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e13675"}}